120321-65-5

Basic information

• Product Name: 4-BUTYLAMINO-3-NITRO-BENZOIC ACID
• Synonyms: 4-BUTYLAMINO-3-NITRO-BENZOIC ACID
• CAS NO: 120321-65-5
• Molecular Formula: C₁₁H₁₄N₂O₄
• Molecular Weight: 238.23986
• Mol File: 120321-65-5.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-BUTYLAMINO-3-NITRO-BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BUTYLAMINO-3-NITRO-BENZOIC ACID(120321-65-5)
• EPA Substance Registry System: 4-BUTYLAMINO-3-NITRO-BENZOIC ACID(120321-65-5)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 120321-65-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Butylamino-3-nitro-benzoic acid is used as an intermediate in the synthesis of pharmaceuticals for its unique chemical properties. It aids in the development of new drugs and contributes to the advancement of medicine.
Used in Dyes Production:
In the dyes industry, 4-Butylamino-3-nitro-benzoic acid is used as a key component in the production of various dyes. Its chemical structure allows for the creation of a wide range of colors and properties, enhancing the versatility and effectiveness of dyes.
Used in Materials Science:
4-Butylamino-3-nitro-benzoic acid is utilized in materials science for its potential applications in developing new materials with unique properties. Its structure and reactivity make it a valuable tool for researchers and chemists in creating innovative materials for various industries.

Upstream product

• 109-73-9 N-butylamine 
• 96-99-1 4-chloro-3-nitrobenzoate 
• 453-71-4 3-nitro-4-fluorobenzoic acid 

Downstream Products

• 120337-90-8 3-amino-4-(butylamino)benzoic acid 
• 1344028-66-5 2-(dimethylamino)ethyl 4-(butylamino)-3-nitrobenzoate 

Relevant articles and documents

Synthesis and biological evaluation of novel dabigatran derivatives as thrombin inhibitors

A novel series of 3-[{2-[(4-carbamimidoylphenylamino)methyl]-1-substituted-1H-benzoimidazole-5-carbonyl}(3-chloro-4-fluorophenyl)amino]propionic derivatives of dabigatran was synthesized. The structures of the compounds were characterized by 1H NMR, 13C NMR, HRMS, and elemental analysis. The compounds were screened for in vitro thrombin inhibitory activity. The results indicated that the compounds had low to moderate inhibitory activity. The compounds with N-methyl and N-ethyl side chains had much greater inhibitory activity against thrombin than those with other side chains.

DERIVATIVES OF TETRACAINE

Disclosed herein are derivatives of tetracaine that, among other things, block cyclic nucleotide gated (CNG) channels and are useful in the treatment of diseases characterized by overactive CNG channels such as retinal degeneration diseases.

Halogen substituents on the aromatic moiety of the tetracaine scaffold improve potency of cyclic nucleotide-gated channel block

A series of new tetracaine derivatives with substituents on the aromatic ring was prepared and evaluated for block of retinal rod cyclic nucleotide-gated (CNG) channels. Aromatic substitutions had little effect starting with the basic tetracaine scaffold,

3-Nitro-4-amino benzoic acids and 6-amino nicotinic acids are highly selective agonists of GPR109b

A series of 3-nitro-4-substituted-aminobenzoic acids were prepared and found to act as potent and highly selective agonists of the orphan human GPCR GPR109b, a low affinity receptor for niacin. No activity was observed at the closely homologous high affinity niacin receptor, GPR109a. A second series, comprising 6-amino-substituted nicotinic acids was, also prepared and several analogues showed comparable activity to the nitroaryl series.

(1H-azol-1-ylmethyl) substituted benzotriazole derivatives and pharmaceutical compositions containing them

(1_H-azol-1-ylmethyl)substituted benzotriazole derivatives, compositions containing the same, and methods of treating estrogen dependent disorders.